A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (F H ...

As part of the strategic partnership, Biocytogen will provide a bispecific antibody derived from its proprietary RenLite ® platform, which is designed to produce fully human bispecific antibodies ...

European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) domain fusion ...

Tissue processing advance can label proteins at the level of individual cells across whole, intact rodent brains and other large samples just as fast and uniformly as in dissociated single cells.

A unique reaction in which antibodies bind to other antibodies may help scientists at Scripps Research better understand how ...

The CuRVE framework and its implementation in eFLASH mark a significant advancement in volumetric single-cell analysis.

Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 ...